BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32278079)

  • 1. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists.
    Lucey M; Pickford P; Bitsi S; Minnion J; Ungewiss J; Schoeneberg K; Rutter GA; Bloom SR; Tomas A; Jones B
    Mol Metab; 2020 Jul; 37():100991. PubMed ID: 32278079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
    Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
    Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists.
    Fletcher MM; Halls ML; Zhao P; Clydesdale L; Christopoulos A; Sexton PM; Wootten D
    Biochem Pharmacol; 2018 Oct; 156():406-419. PubMed ID: 30195733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.
    Marzook A; Chen S; Pickford P; Lucey M; Wang Y; Corrêa IR; Broichhagen J; Hodson DJ; Salem V; Rutter GA; Tan TM; Bloom SR; Tomas A; Jones B
    Biochem Pharmacol; 2021 Aug; 190():114656. PubMed ID: 34129856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
    Thompson A; Stephens JW; Bain SC; Kanamarlapudi V
    PLoS One; 2016; 11(4):e0154229. PubMed ID: 27100083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists.
    Hinds CE; Peace E; Chen S; Davies I; El Eid L; Tomas A; Tan T; Minnion J; Jones B; Bloom SR
    Diabetes Obes Metab; 2024 Jan; 26(1):65-77. PubMed ID: 37795639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide.
    Pickford P; Lucey M; Fang Z; Bitsi S; de la Serna JB; Broichhagen J; Hodson DJ; Minnion J; Rutter GA; Bloom SR; Tomas A; Jones B
    Br J Pharmacol; 2020 Sep; 177(17):3905-3923. PubMed ID: 32436216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
    Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
    Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
    Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
    Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
    Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
    J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
    Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
    Lei S; Meng Q; Liu Y; Liu Q; Dai A; Cai X; Wang MW; Zhou Q; Zhou H; Yang D
    Eur J Pharmacol; 2024 Apr; 968():176419. PubMed ID: 38360293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.
    Hager MV; Clydesdale L; Gellman SH; Sexton PM; Wootten D
    Biochem Pharmacol; 2017 Jul; 136():99-108. PubMed ID: 28363772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational modelling of dynamic cAMP responses to GPCR agonists for exploration of GLP-1R ligand effects in pancreatic β-cells and neurons.
    Bridge L; Chen S; Jones B
    Cell Signal; 2024 Jul; 119():111153. PubMed ID: 38556030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy.
    Zhou Y; Li Z; Cao X; Ma H; White PF; Xu X; Jiang Y; Sun X; Cui Y
    Brain Res; 2019 Mar; 1706():116-124. PubMed ID: 30408479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
    Kanoski SE; Fortin SM; Arnold M; Grill HJ; Hayes MR
    Endocrinology; 2011 Aug; 152(8):3103-12. PubMed ID: 21693680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.
    Chepurny OG; Matsoukas MT; Liapakis G; Leech CA; Milliken BT; Doyle RP; Holz GG
    J Biol Chem; 2019 Mar; 294(10):3514-3531. PubMed ID: 30622136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.